Back to Search Start Over

Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation

Authors :
Antoine Chalopin
Benjamin Ory
Lidia Rodriguez Calleja
Marta Tellez Gabriel
Dominique Heymann
Equipe LIGUE Nationale Contre le Cancer 2012
Physiopathologie des Adaptations Nutritionnelles (PhAN)
Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE)
Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE)
Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)
Centre hospitalier universitaire de Nantes (CHU Nantes)
Department of Oncology and Metabolism [Sheffield, UK]
The University of Sheffield [Sheffield, U.K.]
This paper was written as a part of research project which received funding from the Seventh Framework Program [(FP7/2007-2013) under grant agreement no. 264817—BONE-NET and this work was supported by the Fondation de France (Engt no. 16390)].
European Project: 264817,EC:FP7:PEOPLE,FP7-PEOPLE-2010-ITN,BONE-NET(2011)
Heymann, Dominique
European Training Network on Cancer-Induced Bone Diseases - BONE-NET - - EC:FP7:PEOPLE2011-02-01 - 2015-01-31 - 264817 - VALID
Source :
Clinical Chemistry, Clinical Chemistry, American Association for Clinical Chemistry, 2016, 62 (4), pp.571-581. ⟨10.1373/clinchem.2015.249706⟩, Clinical Chemistry, 2016, 62 (4), pp.571-581. ⟨10.1373/clinchem.2015.249706⟩
Publication Year :
2016
Publisher :
HAL CCSD, 2016.

Abstract

BACKGROUND Circulating tumor cells (CTCs) are biomarkers for noninvasively measuring the evolution of tumor genotypes during treatment and disease progression. Recent technical progress has made it possible to detect and characterize CTCs at the single-cell level in blood. CONTENT Most current methods are based on epithelial cell adhesion molecule (EpCAM) detection, but numerous studies have demonstrated that EpCAM is not a universal marker for CTC detection because it fails to detect both carcinoma cells that undergo epithelial-mesenchymal transition (EMT) and CTCs of mesenchymal origin. Moreover, EpCAM expression has been found in patients with benign diseases. A large proportion of the current studies and reviews about CTCs describe EpCAM-based methods, but there is evidence that not all tumor cells can be detected using this marker. Here we describe the most recent EpCAM-independent methods for enriching, isolating, and characterizing CTCs on the basis of physical and biological characteristics and point out the main advantages and disadvantages of these methods. SUMMARY CTCs offer an opportunity to obtain key biological information required for the development of personalized medicine. However, there is no universal marker of these cells. To strengthen the clinical utility of CTCs, it is important to improve existing technologies and develop new, non–EpCAM-based systems to enrich and isolate CTCs.

Details

Language :
English
ISSN :
00099147 and 15308561
Database :
OpenAIRE
Journal :
Clinical Chemistry, Clinical Chemistry, American Association for Clinical Chemistry, 2016, 62 (4), pp.571-581. ⟨10.1373/clinchem.2015.249706⟩, Clinical Chemistry, 2016, 62 (4), pp.571-581. ⟨10.1373/clinchem.2015.249706⟩
Accession number :
edsair.doi.dedup.....6d9a26b68372ba65ab719f28e940c346